应用线性探针技术与传统药敏试验检测耐药结核病的成本比较

中国防痨杂志 ›› 2013, Vol. 35 ›› Issue (3): 187-190.

应用线性探针技术与传统药敏试验检测耐药结核病的成本比较

李强夏辉欧喜超赵冰逄宇赵雁林

102206 北京，中国疾病预防控制中心结核病预防控制中心国家结核病参比实验室

收稿日期:2012-12-01 出版日期:2013-03-10 发布日期:2013-03-14
通信作者: 赵雁林 E-mail:zhaoyanlin@chinatb.org
基金资助:
中国卫生部与比尔及梅琳达·盖茨基金会结核病防治项目（2009-04-01）

Cost comparison analysis of line probe assay and conventional drug susceptibility testing for diagnosis of drug resistance of Mycobacteria tuberculosis

LI Qiang, XIA Hui, OU Xi-chao, ZHAO Bing, PANG Yu, ZHAO Yan-lin

National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Received:2012-12-01 Online:2013-03-10 Published:2013-03-14
Contact: ZHAO Yan-lin E-mail:zhaoyanlin@chinatb.org

摘要/Abstract

摘要： 目的对比分析线性探针技术（line probe assay，LPA）和传统药敏试验（drug susceptibility testing，DST）在地市级医院实验室检测耐药结核病的成本。方法收集3次LPA和DST在内蒙古第四人民医院、连云港市第四人民医院、开封市肺科医院和永川第二人民医院结核病实验室检测不同样本量时使用的所有成本，包括管理费、建筑设备费、试剂耗材和人工等费用，计算2种方法平均检测1例患者的总成本，比较分析4个实验室分别使用两种方法进行耐药检测的平均成本。两样本间均数差异显著性检验采用t检验，P＜0.05为差异有统计学意义。结果 LPA和DST检测每例患者的平均成本分别为201.0元和365.8元，差异有统计学意义（t=32.28，P<0.01）。LPA和DST检出每例耐多药结核病的单位成本分别为2794.4元和4689.7元，检出1例耐多药结核病，LPA较DST能够节省1895.3元，检测成本明显降低。结论 LPA检测结核病患者耐药性的单位平均成本明显低于DST，可以考虑在地市级结核病医院实验室应用。

关键词: 结核/经济学, 分子诊断技术, 微生物敏感性试验, 成本及成本分析

Abstract: Objective To compare the costs of line probe assay (LPA) and conventional drug susceptibility testing (DST) for detecting the drug resistance of Mycobacteria tuberculosis in prefectural TB hospitals. Methods The full costs related to LPA and conventional DST including management, building, equipment, reagent, consumables and staff were collected from the Fourth People’s Hospital of Inner Mongolia, the Fourth People’s Hospital of Lianyungang City, Kaifeng Lung Hospital and the Second People’s Hospital of Yongchuan District. The average costs of LPA and DST were analyzed by t test, and the level of significance was set to P<0.05. Results The average costs for testing one case by LPA and DST were 201.0 Yuan and 365.8 Yuan respectively. The difference was significant (t=32.28, P<0.01). The unit costs for identifying one MDR-TB case by LPA and DST were 2794.4 Yuan and 4689.7 Yuan respectively. Compared to conventional DST, 1895.3 Yuan could be saved by LPA for detecting one MDR-TB case, and the testing cost was significantly reduced. Conclusion The cost of LPA for detecting drug resistant TB patient was lower than that of DST. It can be applied in prefectural TB laboratory.

Key words: Tuberculosis/economics, Molecular diagnostic techniques, Microbial sensitivity tests, Costs and cost analysis

李强夏辉欧喜超赵冰逄宇赵雁林. 应用线性探针技术与传统药敏试验检测耐药结核病的成本比较[J]. 中国防痨杂志, 2013, 35(3): 187-190.

LI Qiang, XIA Hui, OU Xi-chao, ZHAO Bing, PANG Yu, ZHAO Yan-lin. Cost comparison analysis of line probe assay and conventional drug susceptibility testing for diagnosis of drug resistance of Mycobacteria tuberculosis[J]. Chinese Journal of Antituberculosis, 2013, 35(3): 187-190.

参考文献

［1］Bang DA, Andersen B, Thomsen VO. Rapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J Clin Microbiol, 2006, 44(7):2605-2608.

［2］Tortoli E, Marcelli F. Use of the INNO LiPA Rif. TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis, 2007, 26(1):51-55.

［3］Lacoma A, Garcia-Sierra N, Prat C, et al. GenoType Mtb-DRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol, 2008, 46(11):3660-3667.

［4］World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDR-TB). Geneva: WHO, 2008 ［2009-11-18］. http://www.who.int/tb/dots/laboratory/lpa_policy.pdf.

［5］Sohn H, Minion J, Albert H, et al. TB diagnostic tests: how do we figure out their costs? Expert Rev Anti Infect Ther, 2009, 7(6):723-733.

［6］Kivihya-Ndugga LE, van Cleeff MR, Githui WA, et al. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis, 2003, 7(12):1163-1171.

［7］Sohn H, Sinthuwattanawibool C, Rienthong S, et al. Fluore-scence microscopy is less expensive than Ziehl-Neelsen microscopy in Thailand. Int J Tuberc Lung Dis, 2009,13(2):266-268.

［8］Dowdy DW, Lourenco MC, Cavalcante SC, et al. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One, 2008, 3(12): e4057.

［9］Foundation for Innovative New Diagnostics. FIND prices for GenoType MTBDRplus and Country List. Geneva：Foundation for Innovative New Diagnostics，2009［2012-12-20］. http://www.finddiagnostics.org/programs/find-negotiated-prices.

［10］Ogwang S, Asiimwe BB, Traore H, et al. Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda.BMC Infect Dis, 2009, 9: 139-146.

［11］Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis, 2008, 47(4): 487-495.

[1]	李爱芳, 崔晓利, 康磊, 雷静, 党丽云, 杨翰. 荧光PCR探针熔解曲线法检测结核分枝杆菌耐药性的价值[J]. 中国防痨杂志, 2020, 42(9): 998-1001.
[2]	盛杰, 朱洋, 地里下提·阿不力孜, 唐伟, 古甫丁, 宋兴华. 表型与分子药物敏感性试验对术后耐药骨关节结核患者化疗的指导与效果分析[J]. 中国防痨杂志, 2020, 42(8): 838-844.
[3]	孙晴, 黄海荣, 王桂荣. 贝达喹啉、氯法齐明和德拉马尼对常见致病性非结核分枝杆菌体外抑菌活性及耐药机制的研究进展[J]. 中国防痨杂志, 2020, 42(8): 880-884.
[4]	宋怡蒙, 李远春, 贺文从, 何萍, 包晶晶, 刘春法, 刘东鑫, 王鑫洋, 赵雁林, 李燕明. 荧光PCR探针熔解曲线技术检测MTB耐药性的成本分析[J]. 中国防痨杂志, 2020, 42(7): 712-717.
[5]	包训迪, 江跃, 梁锁, 程红燕, 夏广秀, 王超, 叶倩, 王舒, 王庆. 安徽省非结核分枝杆菌临床分离率及人群分布和耐药性分析[J]. 中国防痨杂志, 2020, 42(7): 718-724.
[6]	张洁, 任怡宣, 潘丽萍, 张宗德. 全基因组测序在结核分枝杆菌研究中的应用[J]. 中国防痨杂志, 2020, 42(7): 737-740.
[7]	马进宝, 任斐, 曾令城, 陈明伟. 2015—2019年西安市680例耐多药结核病患者耐药情况分析[J]. 中国防痨杂志, 2020, 42(6): 609-613.
[8]	张静, 陈曦, 王彬, 付雷, 陆宇, 陈效友. 改良单叠氮丙啶-荧光定量PCR法的建立及其检测抗结核药物活性的价值[J]. 中国防痨杂志, 2020, 42(5): 472-480.
[9]	杨翰,杨静芬,伍浩,崔晓利,党丽云. 微孔板法在一线抗结核药物敏感性试验中的应用价值[J]. 中国防痨杂志, 2020, 42(4): 380-384.
[10]	简奕娈,吴龙章,古卓云. 18例五官非结核分枝杆菌病患者的临床特征及疗效分析[J]. 中国防痨杂志, 2020, 42(3): 255-258.
[11]	陈燕梅,黄新春,孙琦,张晨晨,温文沛,陈亮. 2016年广东省涂阴培阳肺结核患者耐药情况分析[J]. 中国防痨杂志, 2020, 42(3): 272-275.
[12]	蒋明霞, 晁秀珍, 王兆芬, 马斌忠, 马永成, 王蓉, 王朝才, 李尔琛, 魏於家, 李咏雪, 张琪. 青海省南部地区154株结核分枝杆菌临床分离株耐药性检测结果分析[J]. 中国防痨杂志, 2020, 42(12): 1289-1293.
[13]	冯莹, 马进宝, 杨翰, 杨元利, 任斐. 93例结核性脑膜炎患者脑脊液分离株耐药性检测结果分析[J]. 中国防痨杂志, 2020, 42(11): 1177-1182.
[14]	应若嫣, 黄晓辰, 王洁, 刘一典, 沙巍, 杨华. 耐药MTB分离株对不同组合抗结核药品体外药物敏感性试验的结果分析[J]. 中国防痨杂志, 2020, 42(11): 1183-1182.
[15]	杨映晖, 伍定辉, 苏伟明, 董春萍, 姚向阳. 基因芯片法在结核分枝杆菌耐药基因快速诊断中的应用价值[J]. 中国防痨杂志, 2020, 42(11): 1191-1195.